Ayaka Ozaki
Overview
Explore the profile of Ayaka Ozaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuoka I, Kasai T, Onaga C, Ozaki A, Motomura H, Maemura Y, et al.
Oncol Lett
. 2024 Jul;
28(3):426.
PMID: 39021737
Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been identified as a prognostic marker in several types of cancer, including pancreatic cancer. However, to...
2.
Ozaki A, Matsuda A, Maemura Y, Tada Y, Kasai T, Nagashima Y, et al.
Anticancer Res
. 2023 Dec;
44(1):37-47.
PMID: 38160009
Background/aim: We have reported that p62 (also known as sequestosome 1) is needed for survival/proliferation and tumor formation by aldehyde dehydrogenase 1 (ALDH1) -positive cancer stem cells (CSCs) and that...
3.
Okamoto T, Onaga C, Matsuoka I, Ozaki A, Matsuda C, Kasai T, et al.
Cancer Diagn Progn
. 2023 Jul;
3(4):439-448.
PMID: 37405223
Background/aim: High expression of solute carrier family 20 member 1 (SLC20A1) indicates poor clinical outcomes for patients with breast cancer subtypes treated with endocrine therapy and radiotherapy. However, the association...
4.
Kasai T, Tamori S, Takasaki Y, Matsuoka I, Ozaki A, Matsuda C, et al.
Biochem Biophys Res Commun
. 2023 Jun;
669:85-94.
PMID: 37267864
Pancreatic ductal adenocarcinoma (PDAC) is the cancer with the poorest prognosis. One of the major properties reflecting its poor prognosis is high-grade heterogeneity, which leads to insensitivity to anticancer treatments....
5.
Xiong Y, Motomura H, Tamori S, Ozaki A, Onaga C, Hara Y, et al.
Anticancer Res
. 2022 Oct;
42(11):5223-5232.
PMID: 36288878
Background/aim: CD58 is an immune adhesion molecule on the cellular surface. It was previously found that a high expression of CD58 predicted a poor prognosis of patients with lower-grade gliomas....
6.
Onaga C, Tamori S, Matsuoka I, Ozaki A, Motomura H, Nagashima Y, et al.
Cancer Diagn Progn
. 2022 Jul;
2(4):429-442.
PMID: 35813014
Background/aim: Radiotherapy is one of the main treatments for estrogen receptor-positive (ER+) breast cancer. However, in some ER+ breast cancer cases, radiotherapy is insufficient to inhibit progression and there is...
7.
Ozaki A, Motomura H, Tamori S, Onaga C, Nagashima Y, Kotori M, et al.
Anticancer Res
. 2022 Jul;
42(7):3299-3312.
PMID: 35790283
Background/aim: p62 (also known as sequestosome 1) is involved in cancer progression, and high expression of p62 indicates poor clinical outcome in several cancer types. However, the association between p62...
8.
Onaga C, Tamori S, Matsuoka I, Ozaki A, Motomura H, Nagashima Y, et al.
PLoS One
. 2022 May;
17(5):e0268799.
PMID: 35605014
Estrogen receptor-positive (ER+) breast cancer intrinsically confers satisfactory clinical outcomes in response to endocrine therapy. However, a significant proportion of patients with ER+ breast cancer do not respond well to...
9.
Motomura H, Tamori S, Yatani M, Namiki A, Onaga C, Ozaki A, et al.
Anticancer Res
. 2021 Dec;
41(12):5959-5971.
PMID: 34848450
Background/aim: We examined the inhibitory effects of both glyoxalase 1 (GLO 1) and protein kinase C (PKC)λ in aldehyde dehydrogenase 1 (ALDH1)-positive breast cancer stem cells (CSCs). Materials And Methods:...
10.
Motomura H, Ozaki A, Tamori S, Onaga C, Nozaki Y, Waki Y, et al.
Oncol Lett
. 2021 Jun;
22(1):547.
PMID: 34093768
Cancer cells upregulate the expression levels of glycolytic enzymes in order to reach the increased glycolysis required. One such upregulated glycolytic enzyme is glyoxalase 1 (GLO 1), which catalyzes the...